Active substance |
Olipudase alfa |
Domain |
Metabolism and Endocrinology |
Reason of inclusion |
New medicine (specialité) |
Main indication |
Metabolic diseases |
Extended indication |
Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B. |
Proprietary name |
Xenpozyme |
Manufacturer |
Sanofi |
Mechanism of action |
Enzyme replacement therapy |
Route of administration |
Intravenous |
Therapeutical formulation |
Powder for injection / infusion solution |
Budgetting framework |
Intermural (MSZ) |
Centre of expertise |
Amsterdam UMC, lokatie AMC (Sphinx - The Amsterdam Lysosome Center) |